Authors: Boehrer, Simone; Nowak, Daniel; Hoelzer, Dieter; Mitrou, Paris S.; Chow, Kai U.

Source: Current Pharmaceutical Design, Volume 12, Number 1, January 2006 , pp. 111-128(18)

Publisher: Bentham Science Publishers

Abstract:

In hematologic neoplasias primary or secondary resistance of malignant cells towards the applied treatment presents the major clinical obstacle in the induction of remission and definite cure. Evaluation of the underlying molecular mechanisms determining response or resistance not only enables the clinician to define prognostic markers, but moreover facilitates the design of molecularly targeted agents potentially reversing the causative lesion. Deregulation of apoptosis is considered to contribute to the emergence and propagation of the malignant clone, and several molecular alterations hindering programmed cell death and thus leading to chemoresistance have been defined. While reviewing these molecular alterations this article moreover focuses on the impact of new therapeutic agents, which specifically exploit the knowledge of the molecular characteristics of malignant hematopoetic cells.

Keywords: Rituximab; Campath-1H; Imatinib; Monoclonal antibodies; HDAC-Inhibitors; Thalidomide; Nuclide / Toxinconjugated Antibodies; Arsenic Trioxide; Proteasome inhibitors; Antisense Oligonucleotide-Bcl-2

Document Type: Research article

Affiliations: 1: Johann-Wolfgang Goethe University Hospital, Department of Internal Medicine II, Hematology and Oncology, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany;

Publication date: 2006-01-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Boehrer, Simone ;  Nowak, Daniel ;  Hoelzer, Dieter ;  Mitrou, Paris S. ;  Chow, Kai U.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers